Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chuanliang Xu

Showing results (1-10 of 170) with videos related to

Pageof 17
Sort By:
European Urology Focus|June 4, 2024
Re: Riccardo Mastroianni, Gabriele Tuderti, Mariaconsiglia Ferriero, et al. Robot-assisted Radical Cystectomy with Totally Intracorporeal Urinary Diversion Versus Open Radical Cystectomy: 3-Year Outcomes from a Randomised Controlled Trial. Eur Urol 2024;85:422-30Wei He, Shuxiong Zeng, Chuanliang Xu
Nature|July 2, 2024
Streamlined collaboration can boost CRISPR gene therapies for rare diseasesWei He, Shuxiong Zeng, Chuanliang Xu
Translational Andrology and Urology|May 13, 2022
Large population-based study of upper tract urothelial carcinoma in China may provide further insight into the impact of bladder cancer on upper tract urothelial carcinoma's prognosis in Chinese populationShuxiong Zeng, Zhensheng Zhang, Chuanliang Xu
European Urology|November 2, 2023
Re: Mingxiao Feng, Andres Matoso, Gabriel Epstein, et al. Identification of Lineage-specific Transcriptional Factor-defined Molecular Subtypes in Small Cell Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.05.023Ziwei Wang, Shuxiong Zeng, Chuanliang Xu
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 5, 2023
Controversy Surrounding Bladder-Sparing Radical Dose Radiotherapy as an Alternative to Radical Cystectomy for Clinically Node-Positive Nonmetastatic Bladder CancerWei He, Shuxiong Zeng, Chuanliang Xu
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2022
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin as the Gold Standard Neoadjuvant Chemotherapy Regimen for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer Remains ControversialShuxiong Zeng, Zhensheng Zhang, Chuanliang Xu
Asian Journal of Urology|May 9, 2018
Functional and reconstructive urology (part one)Christopher R Chapple, Qiang Fu, Chuanliang Xu
Asian Journal of Urology|July 11, 2018
Functional and reconstructive urology (part two)Christopher R Chapple, Qiang Fu, Chuanliang Xu
Urologic Oncology|December 17, 2008
Differential up-regulation of erythropoietin and its receptor in benign and malignant prostatic tissueChuanliang Xu, Tie Zhou, Miaoxia He, et al.
Oncology Reports|October 25, 2011
Differential expression and function of AR isoforms in prostate cancerRui Zeng, Zhiyong Liu, Yinghao Sun, et al.
Pageof 17

Showing results (1-10 of 170) with videos related to

Sort By:
Pageof 17
European Urology Focus|June 4, 2024
Re: Riccardo Mastroianni, Gabriele Tuderti, Mariaconsiglia Ferriero, et al. Robot-assisted Radical Cystectomy with Totally Intracorporeal Urinary Diversion Versus Open Radical Cystectomy: 3-Year Outcomes from a Randomised Controlled Trial. Eur Urol 2024;85:422-30Wei He, Shuxiong Zeng, Chuanliang Xu
Nature|July 2, 2024
Streamlined collaboration can boost CRISPR gene therapies for rare diseasesWei He, Shuxiong Zeng, Chuanliang Xu
Translational Andrology and Urology|May 13, 2022
Large population-based study of upper tract urothelial carcinoma in China may provide further insight into the impact of bladder cancer on upper tract urothelial carcinoma's prognosis in Chinese populationShuxiong Zeng, Zhensheng Zhang, Chuanliang Xu
European Urology|November 2, 2023
Re: Mingxiao Feng, Andres Matoso, Gabriel Epstein, et al. Identification of Lineage-specific Transcriptional Factor-defined Molecular Subtypes in Small Cell Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.05.023Ziwei Wang, Shuxiong Zeng, Chuanliang Xu
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 5, 2023
Controversy Surrounding Bladder-Sparing Radical Dose Radiotherapy as an Alternative to Radical Cystectomy for Clinically Node-Positive Nonmetastatic Bladder CancerWei He, Shuxiong Zeng, Chuanliang Xu
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2022
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin as the Gold Standard Neoadjuvant Chemotherapy Regimen for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer Remains ControversialShuxiong Zeng, Zhensheng Zhang, Chuanliang Xu
Asian Journal of Urology|May 9, 2018
Functional and reconstructive urology (part one)Christopher R Chapple, Qiang Fu, Chuanliang Xu
Asian Journal of Urology|July 11, 2018
Functional and reconstructive urology (part two)Christopher R Chapple, Qiang Fu, Chuanliang Xu
Urologic Oncology|December 17, 2008
Differential up-regulation of erythropoietin and its receptor in benign and malignant prostatic tissueChuanliang Xu, Tie Zhou, Miaoxia He, et al.
Oncology Reports|October 25, 2011
Differential expression and function of AR isoforms in prostate cancerRui Zeng, Zhiyong Liu, Yinghao Sun, et al.
Pageof 17